Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in South Dakota: - Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in South Dakota: - Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in South Dakota: - Avera Medical Group — Sioux Falls, South Dakota
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in South Dakota: - Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in South Dakota: - Avera Medical Group — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in South Dakota: - Sanford Cancer Center — Sioux Falls, South Dakota
- Avera Medical Group Cancer Institute — Sioux Falls, South Dakota
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naï…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165070
Sites in South Dakota: - Sanford Cancer Center ( Site 0038) — Sioux Falls, South Dakota
Phase 1, Phase 2 Recruiting Industry
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) trea…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07227597
Sites in South Dakota: - Avera Cancer Institute- Research ( Site 0104) — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this st…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07252739
Sites in South Dakota: - Sanford Cancer Center Oncology Clinic ( Site 0038) — Sioux Falls, South Dakota
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in South Dakota: - Sanford Cancer Center — Sioux Falls, South Dakota
- Sanford USD Medical Center — Sioux Falls, South Dakota
Phase 1 Recruiting Industry
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expa…
Sponsor: Amgen
NCT ID: NCT07037758
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Dakota: - Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in South Dakota: - Monument Health Rapid City Hospital — Rapid City, South Dakota
Recruiting Industry
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-c…
Sponsor: Freenome Holdings Inc.
NCT ID: NCT06122077
Sites in South Dakota: - Circle Clinical Research — Pierre, South Dakota
Recruiting Academic/Other
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim…
Sponsor: Avera McKennan Hospital & University Health Center
NCT ID: NCT05142033
Sites in South Dakota: - Avera Cancer Institute - Aberdeen — Aberdeen, South Dakota
- Avera Cancer Institute - Mitchell — Mitchell, South Dakota
- Avera Cancer Institute - Pierre — Pierre, South Dakota
- Avera Cancer Institute — Sioux Falls, South Dakota
- Avera Cancer Institute - Yankton — Yankton, South Dakota